Trinity Biotech ( NASDAQ: TRIB ) on Friday announced that it has acquired a 12.5% equity stake in Novus Diagnostics, valued at about $2.5 million.
Novus Diagnostics is a company that pioneers a rapid sepsis testing platform. Novus’ platform addresses key limitations in current sepsis.
